Search

Your search keyword '"Endari (Medication)"' showing total 52 results
Start Over Descriptor "Endari (Medication)" Topic sickle cell anemia -- drug therapy
52 results on '"Endari (Medication)"'

1. Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Subjects
United States. Food and Drug Administration, Sickle cell anemia -- Drug therapy, Regulatory compliance, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., July 12, 2024 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTCPK: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced receiving the coveted [...]

Published
2024

2. Emmaus Life Sciences submits MAA to Saudi Food and Drug Authority

Subjects
Glutamine, Drug approval, Sickle cell anemia -- Drug therapy, Business, News, opinion and commentary, Endari (Medication)
Abstract

Emmaus Life Sciences announced the submission of an application to the Saudi Food and Drug Authority for Marketing Authorization for Endari in the Kingdom of Saudi Arabia. This follows Emmaus' [...]

Published
2020

3. Emmaus Life Sciences' Endari receives Florida Medicaid Preferred Drug List approval

Subjects
Sickle cell anemia -- Drug therapy, Medicaid, Glutamine, Drug approval, Business, Endari (Medication)
Abstract

M2 EQUITYBITES-March 30, 2022-Emmaus Life Sciences' Endari receives Florida Medicaid Preferred Drug List approval (C)2022 M2 COMMUNICATIONS http://www.m2.com Emmaus Life Sciences, Inc. (OTCQX: EMMA), a US-based company involved in the [...]

Published
2022

4. Emmaus Life Sciences' Endari receives Florida Medicaid Preferred Drug List approval

Subjects
Sickle cell anemia -- Drug therapy, Medicaid, Glutamine, Drug approval, Chemistry, Endari (Medication)
Abstract

M2 PHARMA-March 30, 2022-Emmaus Life Sciences' Endari receives Florida Medicaid Preferred Drug List approval (C)2022 M2 COMMUNICATIONS Emmaus Life Sciences, Inc. (OTCQX: EMMA), a US-based company involved in the treatment [...]

Published
2022

5. Emmaus Life Sciences Announces Submission of Endari(r) Marketing Authorization Application in Kuwait

Subjects
Sickle cell anemia -- Drug therapy, Drug approval, Food supply, Marketing, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE: Emmaus Life Sciences, Inc. has issued the following news release: Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, [...]

Published
2021

6. Emmaus Life Sciences Announces Submission of Endari Marketing Authorization Application in Kuwait

Subjects
Sickle cell anemia -- Drug therapy, Glutamine, Drug approval, Food supply, Marketing, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., July 15, 2021 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of [...]

Published
2021

7. Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari to the Saudi Food & Drug Authority

Subjects
Sickle cell anemia -- Drug therapy, Glutamine, Drug approval, Marketing, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., May 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its [...]

Published
2021

8. FDA Approves Updated Label for Endari(r)

Subjects
Labels, Drug approval, Sickle cell anemia -- Drug therapy, General interest, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE: Emmaus Life Sciences, Inc. has issued the following press release: Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today revised prescribing information for [...]

Published
2020

9. FDA Approves Updated Label for Endari

Subjects
Sickle cell anemia -- Drug therapy, Drug approval, Labels, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Nov. 3, 2020 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today revised prescribing information for Endari to better inform healthcare [...]

Published
2020

11. UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

Subjects
Glutamine, Marketing, Drug approval, Sickle cell anemia -- Drug therapy, Advertising, marketing and public relations, Endari (Medication)
Abstract

(GlobeNewswire) - Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) [...]

Published
2020

14. UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

Subjects
Glutamine, Marketing, Drug approval, Sickle cell anemia -- Drug therapy, Banking, finance and accounting industries, Business, Endari (Medication)
Abstract

TORRANCE, Calif., Aug 18, 2020 (GLOBE NEWSWIRE via COMTEX) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application [...]

Published
2020

15. Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

Subjects
Glutamine, Marketing, Drug approval, Sickle cell anemia -- Drug therapy, Banking, finance and accounting industries, Business, Endari (Medication)
Abstract

TORRANCE, Calif., Aug 18, 2020 (GLOBE NEWSWIRE via COMTEX) -- Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today the submission of an application [...]

Published
2020

16. Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari

Subjects
Drug approval, Sickle cell anemia -- Drug therapy, Business, international, Endari (Medication)
Abstract

(GlobeNewswire) - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the [...]

Published
2020

17. Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari

Subjects
Drug approval, Sickle cell anemia -- Drug therapy, Business, international, Law, Endari (Medication)
Abstract

(GlobeNewswire) - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European Medicines Agency (EMA) issued scientific advice to Emmaus regarding the [...]

Published
2020

18. Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari(TM)

Subjects
Drug approval, Sickle cell anemia -- Drug therapy, Banking, finance and accounting industries, Business, Endari (Medication)
Abstract

TORRANCE Calif., July 29, Jul 29, 2020 (GLOBE NEWSWIRE via COMTEX) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that the European [...]

Published
2020

20. Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region

Subjects
Glutamine, Sickle cell anemia -- Drug therapy, Insurance industry, Powders (Particulate matter), General interest, News, opinion and commentary, Endari (Medication)
Abstract

California: Emmaus Life Sciences has issued the following press release: Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it expects to receive [...]

Published
2019

21. Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region

Subjects
Glutamine, Sickle cell anemia -- Drug therapy, Insurance industry, Powders (Particulate matter), Business, international, Law, Endari (Medication)
Abstract

(GlobeNewswire) - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba [...]

Published
2019

22. Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region

Subjects
Glutamine, Sickle cell anemia -- Drug therapy, Insurance industry, Powders (Particulate matter), Banking, finance and accounting industries, Business, Endari (Medication)
Abstract

TORRANCE, Calif., Dec 23, 2019 (GLOBE NEWSWIRE via COMTEX) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it expects to receive [...]

Published
2019

23. Endari® Granted Orphan Drug Status in Switzerland

Subjects
Quality control, Orphan drugs, Sickle cell anemia -- Drug therapy, Quality control, Advertising, marketing and public relations, Endari (Medication)
Abstract

2020 DEC 19 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell [...]

Published
2020

24. Emmaus wins Endari's orphan drug status in Switzerland

Subjects
Orphan drugs, Sickle cell anemia -- Drug therapy, Business, Endari (Medication)
Abstract

M2 EQUITYBITES-December 4, 2020-Emmaus wins Endari's orphan drug status in Switzerland (C)2020 M2 COMMUNICATIONS http://www.m2.com Sickle cell disease treatment company Emmaus Life Sciences Inc (OTC:EMMA) reported on Thursday the receipt [...]

Published
2020

25. Emmaus wins Endari's orphan drug status in Switzerland

Subjects
Orphan drugs, Sickle cell anemia -- Drug therapy, Chemistry, Endari (Medication)
Abstract

M2 PHARMA-December 4, 2020-Emmaus wins Endari's orphan drug status in Switzerland (C)2020 M2 COMMUNICATIONS Sickle cell disease treatment company Emmaus Life Sciences Inc (OTC:EMMA) reported on Thursday the receipt of [...]

Published
2020

26. Emmaus Life Sciences Reinforces Positive Outcomes of Endari Clinical Trials, Including Efficacy Findings That Led to FDA Approval

Subjects
Sickle cell anemia -- Drug therapy, Medical research, Medicine, Experimental, Glutamine -- Product development, Clinical trials, Drug approval, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Sept. 24, 2019 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease (SCD) treatment, today released the following summary review of the clinical trials [...]

Published
2019

27. Emmaus Life Sciences Announces Withdrawal of Marketing Authorization Application to European Medicines Agency

Subjects
Sickle cell anemia -- Drug therapy, Glutamine, Drug approval, Marketing, Business, News, opinion and commentary, Endari (Medication)
Abstract

TORRANCE, Calif., Sept. 19, 2019 /PRNewswire/ --Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, today announced the withdrawal of its marketing authorization application (MAA) to [...]

Published
2019

28. EMA'S CHMP OFFERS NEGATIVE OPINION FOR SICKLE CELL DRUG APPROVED BY US FDA

Subjects
United States. Food and Drug Administration, Glutamine, Edaravone, Drugs, Abaloparatide, Ambrisentan, Trientine, Drug approval, Sickle cell anemia -- Drug therapy, Betrixaban, Marketing, Brand names, News, opinion and commentary, Endari (Medication), Radicava (Medication)
Abstract

ROCKVILLE, MD -- The following information was released by the Regulatory Affairs Professionals Society: By Zachary Brennan In a sign that the European Medicines Agency's (EMA) Committee for Medicinal Products [...]

Published
2019

29. Endari Is a Proven Safe and Effective Sickle Cell Treatment

Subjects
United States. Food and Drug Administration, Sickle cell anemia -- Drug therapy, Genes, General interest, News, opinion and commentary, Endari (Medication)
Abstract

LOS ANGELES: LA BioMed has issued the following press release: Last night's episode of CBS' '60 Minutes' brought much-needed awareness of the hardships faced by the estimated 25 million people [...]

Published
2019

30. Endari Is a Proven Safe and Effective Sickle Cell Treatment

Subjects
United States. Food and Drug Administration, Sickle cell anemia -- Drug therapy, Business, News, opinion and commentary, Endari (Medication)
Abstract

Product developed at LA BioMed is a safe, economical, available primary therapy LOS ANGELES, March 11, 2019 /PRNewswire/ -- Last night's episode of CBS' '60 Minutes' brought much-needed awareness of [...]

Published
2019

31. FDA Approves Updated Label for Endari®

Subjects
United States. Food and Drug Administration, Hydroxyurea, Labels, Drug approval, Sickle cell anemia -- Drug therapy, Business, Health, Health care industry, Endari (Medication)
Abstract

2020 NOV 22 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle [...]

Published
2020

32. Emmaus Life Sciences revises Endari prescribing information

Subjects
Drug approval, Sickle cell anemia -- Drug therapy, Chemistry, Endari (Medication)
Abstract

M2 PHARMA-November 4, 2020-Emmaus Life Sciences revises Endari prescribing information (C)2020 M2 COMMUNICATIONS Emmaus Life Sciences Inc (OTC: EMMA), a company involved sickle cell disease treatment, has revised prescribing information [...]

Published
2020

33. Emmaus Life Sciences revises Endari prescribing information

Subjects
Drug approval, Sickle cell anemia -- Drug therapy, Business, Endari (Medication)
Abstract

M2 EQUITYBITES-November 4, 2020-Emmaus Life Sciences revises Endari prescribing information (C)2020 M2 COMMUNICATIONS http://www.m2.com Emmaus Life Sciences Inc (OTC: EMMA), a company involved sickle cell disease treatment, has revised prescribing [...]

Published
2020

34. Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Sponsor the 46th Annual National Sickle Cell Disease Association of America Convention in Baltimore

Subjects
Conferences and conventions, Associations, Sickle cell anemia -- Drug therapy, Business, Business, international, Endari (Medication)
Abstract

TORRANCE, Calif. -- Emmaus Life Sciences, Inc. (Emmaus) is a proud sponsor of the upcoming 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention to be held in [...]

Published
2018

35. Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Present at the Seventh Annual Sickle Cell Disease Therapeutics Conference in New York City on September 13th

Subjects
Conferences and conventions, Glutamine, Sickle cell anemia -- Drug therapy, General interest, News, opinion and commentary, Sickle Cell Disease Association of America, Endari (Medication)
Abstract

NEW YORK: Emmaus Life Sciences, Inc. has issued the following press release: Emmaus Life Sciences, Inc. (Emmaus), after making significant inroads into the sickle cell patient population with the launch [...]

Published
2018

36. Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Present at the Seventh Annual Sickle Cell Disease Therapeutics Conference in New York City on September 13th

Subjects
Conferences and conventions, Glutamine, Child health, Sickle cell anemia -- Drug therapy, Business, Business, international, Sickle Cell Disease Association of America, Endari (Medication)
Abstract

NEW YORK -- Emmaus Life Sciences, Inc. (Emmaus), after making significant inroads into the sickle cell patient population with the launch of Endari[TM] (L-glutamine oral powder), indicated to reduce the [...]

Published
2018

37. Emmaus Life Sciences Announces Opening of Office in New York to Support Endari Launch

Subjects
United States. Food and Drug Administration, Glutamine, Medicaid, Drug approval, Sickle cell anemia -- Drug therapy, Business, Business, international, Endari (Medication)
Abstract

NEW YORK -- Emmaus Life Sciences (Emmaus) announced today it has opened an office in Midtown Manhattan to support the commercial launch of Endari(TM) (L-glutamine oral powder). Endari is an [...]

Published
2018

38. Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine)

Subjects
Glutamine, Marketing, Sickle cell anemia -- Drug therapy, Business, Business, international, European Union, Endari (Medication)
Abstract

TORRANCE, Calif. -- Emmaus Life Sciences, Inc. (Emmaus) announced today that the company's Marketing Authorization Application (MAA) for Xyndari has been fully validated and is now under assessment by the [...]

Published
2018

39. GPB Capital Completes $30 Million Debt Investment in Emmaus Life Sciences

Subjects
United States. Food and Drug Administration, Drug approval, Sickle cell anemia -- Drug therapy, Company investment, General interest, News, opinion and commentary, Endari (Medication)
Abstract

NEW YORK: GPB Capital has issued the following news release: GPB Capital Holdings, LLC (GPB Capital) announced today that it has made a debt investment in Emmaus Life Sciences, Inc. [...]

Published
2018

40. GPB Capital Completes $30 Million Debt Investment in Emmaus Life Sciences

Subjects
United States. Food and Drug Administration, Sickle cell anemia -- Drug therapy, Drug approval, Investments, Company investment, Business, News, opinion and commentary, Endari (Medication)
Abstract

Proceeds from Senior Secured Convertible Note Will Provide Emmaus with Capital to Launch its FDA-Approved Oral Treatment for Sickle Cell Disease NEW YORK, Jan. 18, 2018 /PRNewswire/ -- GPB Capital [...]

Published
2018

41. Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency

Subjects
Drugs, Pediatrics, Sickle cell anemia -- Drug therapy, Company legal issue, Business, Business, international, European Union -- Investigations, Endari (Medication)
Abstract

TORRANCE, Calif. -- Emmaus Life Sciences announced today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP) for its treatment [...]

Published
2017

42. Emmaus Medical, Inc. Announces Availability of Endari for Treatment of Sickle Cell Disease

Subjects
United States. Food and Drug Administration, Glutamine, Drug approval, Sickle cell anemia -- Drug therapy, General interest, News, opinion and commentary, American Society of Hematology, Endari (Medication)
Abstract

ATLANTA:Emmaus Life Sciences, Inc. has issued the following news release: Today at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, Emmaus announced availability of [...]

Published
2017

43. Emmaus Medical, Inc. Announces Availability of Endari[TM] for Treatment of Sickle Cell Disease

Subjects
United States. Food and Drug Administration, Glutamine, Drug approval, Sickle cell anemia -- Drug therapy, Business, Business, international, American Society of Hematology, Endari (Medication)
Abstract

ATLANTA -- Today at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, Emmaus announced availability of Endari (L-glutamine oral powder) for sickle cell disease [...]

Published
2017

44. Emmaus Life Sciences Reinforces Positive Outcomes of Endari ® Clinical Trials, Including Efficacy Findings That Led to FDA Approval

Subjects
United States. Food and Drug Administration, Clinical trials, Glutamine -- Product development, Medical research, Drug approval, Sickle cell anemia -- Drug therapy, Insurance industry, Marketing, Nonprescription drugs, Media executives, Chairpersons, Editors, Business, Pharmaceuticals and cosmetics industries, Health, Endari (Medication)
Abstract

2019 OCT 7 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease (SCD) treatment, [...]

Published
2019

45. Endari Is a Proven Safe and Effective Sickle Cell Treatment

Subjects
Sickle cell anemia -- Drug therapy, Genes, Anopheles, Editors, Insurance, Health care industry, Endari (Medication)
Abstract

2019 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Health Insurance Week -- Last night's episode of CBS' '60 Minutes' brought much-needed awareness of the hardships faced [...]

Published
2019

46. Emmaus Life Sciences, a Leader in Sickle Cell Disease Treatment, to Sponsor the 46th Annual National Sickle Cell Disease Association of America Convention in Baltimore

Subjects
Conferences and conventions, Associations, Sickle cell anemia -- Drug therapy, Corporate sponsorship, Business, Pharmaceuticals and cosmetics industries, Health, Endari (Medication)
Abstract

2018 OCT 22 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Emmaus Life Sciences, Inc. (Emmaus) is a proud sponsor of the upcoming 46th Annual [...]

Published
2018

47. Emmaus Life Sciences Partners with DMS Pharmaceutical Group to Provide Endari™ L-glutamine oral powder to Military Personnel and Beneficiaries for Treatment of Sickle Cell Disease

Subjects
United States. Department of Defense, Military personnel, Nonprescription drugs -- Distribution agreements, Glutamine -- Distribution agreements, Powders (Particulate matter), Sickle cell anemia -- Drug therapy, Beneficiaries, Military bases, Business, Government, Political science, Endari (Medication)
Abstract

2018 AUG 16 (VerticalNews) -- By a News Reporter-Staff News Editor at Politics & Government Business -- Emmaus Life Sciences (Emmaus) announces it has entered into a distribution agreement with [...]

Published
2018

48. Emmaus Life Sciences Announces Opening of Office in New York to Support Endari Launch

Subjects
United States. Food and Drug Administration, Glutamine, Medicaid, Drug approval, Sickle cell anemia -- Drug therapy, Health care industry, Endari (Medication)
Abstract

2018 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Managed Care Business Week -- Emmaus Life Sciences (Emmaus) announced it has opened an office in Midtown Manhattan [...]

Published
2018

49. Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari oral glutamine

Subjects
Glutamine, Marketing, Sickle cell anemia -- Drug therapy, Advertising, marketing and public relations, European Union, Endari (Medication)
Abstract

2018 MAR 31 (VerticalNews) -- By a News Reporter-Staff News Editor at Marketing Weekly News -- Emmaus Life Sciences, Inc. (Emmaus) announced that the company's Marketing Authorization Application (MAA) for [...]

Published
2018

50. Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency

Subjects
Drugs, Pediatrics, Sickle cell anemia -- Drug therapy, Company legal issue, Business, Government, Political science, European Union -- Investigations, Endari (Medication)
Abstract

2018 JAN 4 (VerticalNews) -- By a News Reporter-Staff News Editor at Politics & Government Business -- Emmaus Life Sciences announced that the Paediatric Committee (PDCO) of the European Medicines [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results